RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more about RXRX stock here.

Recursion Pharmaceuticals, Inc. is upgraded to Buy, supported by promising REC-4881 data and strong institutional backing. REC-4881's Phase 1b/2 data in FAP show a 43% median polyp reduction, ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

Community driven content discussing all aspects of software development from DevOps to design patterns. The factorial of 5 is 120. The factorial of 10 is 3,628,800. Programmers can take one of two ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...